China NMPA Drug Inspection - Shunquanlong (Anguo) Pharmaceutical Co., Ltd. - Privet

On October 20, 2023, the National Medical Products Administration (NMPA) released Announcement No. 51, identifying fifteen batches of drugs that failed to meet established quality standards. The non-compliant products were produced by fifteen different companies, including Ulanhot Zhongmeng Pharmaceutical Co., Ltd., Hangzhou Huadong Traditional Chinese Medicine Pieces Co., Ltd., and Beijing Heyanling Pharmaceutical Development Co., Ltd., among others. The findings were based on tests conducted by the China National Institutes for Food and Drug Control and other regional institutes. Key violations identified across the drug batches included issues with dissolution times, moisture content, and content determination. Specifically, some products failed to meet standards for appearance and identification, which are critical for ensuring the efficacy and safety of pharmaceutical products. Operating under the 'Drug Administration Law of the People's Republic of China,' the NMPA has mandated that the involved companies implement immediate risk control measures. These required actions include the suspension of sales and use, as well as the initiation of product recalls for the affected batches. Additionally, the companies must conduct root-cause investigations and implement effective rectifications. Provincial regulatory authorities have been directed to investigate potential illegal activities and publicly disclose the results of these inquiries.